Tissue Regenix Group Plc trades on the London Stock Exchange under the ticker TRX, representing a speculative micro-cap position in the healthcare sector. The share price has attracted attention from investors tracking AIM-listed medtech stocks, with recent data showing significant volatility and a dramatic decline from previous levels.
Understanding the current Tissue Regenix share price requires examining multiple data points, including trading ranges, analyst targets, and the broader context of the company’s market position. This article consolidates available information on TRX.LSE trading activity, financial metrics, and market sentiment.
What is the Current Tissue Regenix Share Price (TRX.LSE)?
As of the most recent data updated around April 8, 2026, Tissue Regenix shares trade at 7.25p on the London Stock Exchange. The company operates with ordinary shares of 0.1p denomination, representing a micro-cap investment opportunity with a market capitalisation of approximately £5.18m. Trading activity on the LSE reflects ongoing interest in the healthcare sector stock despite its small capitalisation base.
7.25p
£5.18m
~81%
LSE
Historical trading data reveals the magnitude of price movement experienced by Tissue Regenix investors. Earlier snapshots from July 2025 showed the share price fluctuating between 36.97p and 40.96p, with a closing price of 38.00p on July 24, 2025. Volume during that session reached approximately 43,000 shares, representing roughly £1.62m in traded value. The contrast with current levels highlights the volatility facing shareholders in this medtech listing.
Key Financial Metrics
Several valuation metrics provide context for assessing Tissue Regenix’s market position. The enterprise value stands at £12.00m, while trailing twelve-month revenue totals $28.65m. These figures situate the company within the healthcare sector, though with notable characteristics distinguishing it from larger peers.
- Price/Book ratio: 1.1x compared to sector average of 1.8x
- Price/LTM Sales: 1.1x versus sector average of 5.2x
- P/E Ratio: -31.3x (sector average: -4.1x)
- EV/EBITDA: 41.09
- 200-Day Moving Average: Currently aligned with 7.25p closing price
- One-year performance: -86.57%, underperforming FTSE All-Share by -88.75%
The negative P/E ratio reflects the company’s current unprofitability, a common characteristic among development-stage medtech firms. Comparing valuation multiples to sector averages suggests the market has priced Tissue Regenix at a discount relative to revenue and book value metrics.
Historical resistance and support levels from July 2025 trading ranged from 34.65p (S3 support) to 42.64p (R3 resistance). Current prices reflect a significant decline below even the lowest identified support level from that period.
Tissue Regenix Share Price Snapshot
| Metric | Value |
|---|---|
| Ticker | TRX |
| Exchange | London Stock Exchange |
| Share Type | Ordinary shares (0.1p) |
| Current Price | 7.25p |
| Market Capitalisation | £5.18m |
| Enterprise Value | £12.00m |
| Revenue (TTM) | $28.65m |
| 1-Year Performance | -86.57% |
Tissue Regenix Share Price Prediction
Analyst coverage of Tissue Regenix provides limited but notable perspective on potential price movements. Available forecasts focus primarily on near-term trading ranges and longer-term target prices, though investors should approach such predictions with appropriate caution given the speculative nature of micro-cap healthcare stocks.
Analyst Targets and Forecasts
One analyst source has established a target price of 85.00p, representing potential upside of approximately 1,072% from current levels around 7.25p. This target appears on community trading platforms, and investors should verify whether this represents current consensus or historical commentary. Additional upside estimates include 228.8% based on analyst targets and 278.9% when comparing to sector performance metrics.
Earnings per share forecasts for the coming year project a loss of -$0.01 per share, consistent with the negative P/E ratio observed in current valuation metrics. Short-term technical analysis from mid-2025 data suggested a potential decline of -9.36% over a three-month horizon, with expected trading ranges between 22.36p and 35.29p at 90% probability. Support levels were identified at 32.50p, 32.00p, and 29.50p during that period.
Analyst targets for micro-cap stocks like Tissue Regenix often carry higher uncertainty than those for larger, more liquid companies. The 85.00p target represents a single source projection rather than consolidated analyst consensus. Investors should conduct independent research before making investment decisions.
Technical indicators show the 200-day moving average currently matches the last closing price of 7.25p, suggesting the share price has converged with its medium-term trend line. This alignment may indicate either stabilised pricing or potential further downside depending on broader market conditions and company-specific developments.
Factors Influencing Price Movement
Several broader market factors can influence Tissue Regenix share price performance. Interest rate environments, as measured by indicators such as the 10 Year Gilt Yield, affect valuations across growth sectors including healthcare. Market sentiment metrics like the Fear and Greed Index can also impact trading behaviour in speculative segments.
Sector-specific factors for medtech companies include clinical trial results, regulatory approvals, partnership announcements, and reimbursement decisions. Company-level developments such as revenue growth, cost management, and strategic transactions can all influence share price trajectories.
Latest Tissue Regenix Share Price News and RNS
Publicly available search results contain limited specific information regarding Regulatory News Service (RNS) announcements for Tissue Regenix. Investors seeking official company communications should consult the Investegate platform, which publishes RNS announcements for LSE-listed companies including those on AIM.
Navigating Official Announcements
The London Stock Exchange maintains official channels for corporate announcements, ensuring investors receive timely disclosure of material events. Regular RNS categories for companies like Tissue Regenix typically include half-year and full-year results, shareholder meetings, director dealings, and any strategic transactions that may arise.
Investors should verify information obtained from third-party sources against official LSE announcements to ensure accuracy and timeliness. Data timestamps on community forums and financial platforms may not reflect real-time developments.
Information Availability
Several data sources show varying levels of currency, with some datasets referencing July 2025 data while others claim updates through April 2026. This temporal inconsistency underscores the importance of consulting multiple authoritative sources and noting publication dates when evaluating Tissue Regenix share price information.
Financial data for micro-cap stocks may not update as frequently as larger listings. Investors should check publication timestamps and consider verifying current prices through the London Stock Exchange website or official company channels before making investment decisions.
Tissue Regenix Takeover Rumours and Updates
Search results contain no confirmed information regarding takeover activity involving Tissue Regenix. Corporate transactions in the healthcare sector do occur periodically, with larger players acquiring innovative technologies from smaller developers. However, specific takeover approaches, negotiations, or concluded transactions for Tissue Regenix have not appeared in the available public record.
M&A Context in Medtech
The medical technology sector has experienced consolidation in recent years, with larger healthcare companies acquiring firms possessing differentiated technologies or market access. Such transactions can benefit target company shareholders through acquisition premiums, though they also carry execution risk and regulatory uncertainty.
Any material corporate transaction involving Tissue Regenix would require disclosure through the company’s RNS channel. Investors monitoring for potential developments should check Investegate for official announcements from the company.
Tissue Regenix Share Price Chat and Community Insights
Community trading platforms host discussions regarding Tissue Regenix shares, though specific forum content has not appeared in available search results. Sources such as ADVFN provide share chat functionality where investors share perspectives, though sentiment expressed in such forums should be treated with appropriate scepticism.
Evaluating Community Information
Information shared on investor chat forums varies significantly in accuracy, timeliness, and potential ulterior motivation. Participants may include company insiders, professional traders, retail investors, and parties with conflicting interests. Verification against official sources remains essential for any investment-relevant claims.
The absence of specific chat forum content in current search results may reflect platform indexing patterns rather than absence of discussion. Investors interested in community perspectives should visit specific forum platforms directly, noting that such discussions do not constitute investment advice.
Price History Timeline
Available historical data provides limited but instructive context regarding Tissue Regenix share price evolution. Aggregate historical records show trades executed across a wide range from 0.5p to 175p levels, indicating substantial price discovery over the company’s listing history.
- January 7, 2025: Asset Match admission recorded at 0.1p per share, marking an official listing milestone.
- July 24, 2025: Trading at 38.00p with intraday range of 36.97p to 40.96p; volume approximately 43,000 shares.
- October 15, 2025: Analyst forecast post published on community platforms indicating 85.00p price target.
- April 8, 2026: Most recent data point showing price at 7.25p and market capitalisation of £5.18m.
The trajectory from 38.00p in mid-2025 to 7.25p in April 2026 represents an 81% decline over approximately nine months. This severe contraction significantly exceeds broader market movements and warrants investigation into underlying company or sector-specific factors.
Complete price history with verified timestamps has not been fully documented in available sources. The timeline above represents data points captured through various financial platforms and may not include intermediate significant price movements.
What We Know and What Remains Uncertain
Transparency regarding information quality helps investors make informed decisions. The following assessment distinguishes established facts from areas where uncertainty persists.
| Established Information | Uncertain or Unavailable |
|---|---|
| Current price: 7.25p on LSE (April 2026) | Full 52-week trading high and low |
| Market capitalisation: £5.18m | Consolidated analyst consensus beyond single 85p target |
| Ticker: TRX, ordinary shares 0.1p | Current RNS announcements content |
| Revenue (TTM): $28.65m | Takeover approach status |
| Enterprise value: £12.00m | Specific chat forum sentiment |
| Historical trading at 0.5p to 175p levels | Connection to “SBTX” ticker if any |
Investors should note that data appearing in current sources shows temporal inconsistency, with some datasets referencing July 2025 and others claiming April 2026 updates. The most conservative approach involves assuming significant change may have occurred between historical and current data points.
Sector Context and Market Dynamics
Tissue Regenix operates within the medical technology segment of the healthcare sector. This space encompasses companies developing diagnostic technologies, medical devices, and tissue engineering solutions. Peer companies in broader medtech comparisons include firms such as those with established product portfolios and commercial revenue streams.
The micro-cap classification places Tissue Regenix among the smallest publicly traded companies, where trading volumes may be limited and bid-ask spreads wider than for larger capitalisation stocks. Such characteristics can amplify price movements in either direction and create execution challenges for larger orders.
LSE AIM listing provides a regulatory framework for smaller growth companies, offering exposure to public markets while maintaining lighter disclosure requirements than the main market. Companies admitted through platforms such as Asset Match undergo admission processes that provide certain listing credentials to potential investors.
Sources and Market Data
Financial data for this analysis derives from multiple platforms including Stockopedia, Investing.com, ADVFN, Intelligent Investor, and the London Stock Exchange. Each source maintains different update frequencies and data collection methodologies, contributing to the observed variation in timestamp references.
The London Stock Exchange represents the authoritative source for TRX.LSE pricing, with real-time data available through professional terminals and the exchange’s consumer-facing platforms.
“The one analyst source indicates a price target of 85.00p”
— ADVFN community platform, October 15, 2025
Analyst commentary for micro-cap healthcare stocks typically originates from fewer sources than for larger capitalisation companies. The limited analyst coverage observed for Tissue Regenix reflects the challenges facing research houses in maintaining coverage for smaller, less liquid positions.
Summary and Outlook
Tissue Regenix Group Plc trades at 7.25p on the London Stock Exchange as a speculative micro-cap healthcare investment. The share price has experienced substantial decline from July 2025 levels around 38.00p, resulting in significant losses for holders during that period. Current valuation metrics suggest pricing at a discount to sector averages on price/book and price/sales bases, though the negative earnings position limits traditional valuation comparisons.
Analyst targets placing fair value at 85.00p exist but represent limited coverage from single sources. Investors considering Tissue Regenix should monitor official RNS announcements for material corporate developments, verify current pricing through LSE platforms, and assess personal risk tolerance for speculative micro-cap investments. Broader market indicators including interest rate trends and sector sentiment can influence price movements for healthcare stocks of this size.
Frequently Asked Questions
What is Tissue Regenix RNS?
RNS refers to the Regulatory News Service operated by the London Stock Exchange. Companies listed on AIM use RNS to publish official announcements including financial results, director changes, and material corporate events. Investors can access Tissue Regenix RNS announcements through Investegate.
Is there a Tissue Regenix takeover?
Public search results do not confirm any takeover activity involving Tissue Regenix. Any material transaction would require disclosure through official RNS channels. The absence of reported takeover approaches does not preclude unannounced discussions or future possibilities.
What is SBTX share price?
Search results contain no information connecting “SBTX” to Tissue Regenix. This may represent a different ticker symbol or unrelated security. Tissue Regenix trades under the ticker TRX on the London Stock Exchange.
How often does Tissue Regenix share price update?
Tissue Regenix trades during standard LSE trading hours with real-time pricing available through exchange platforms and financial data providers. Update frequency varies by source, with some platforms showing delays while others provide streaming data.
What happened to the Tissue Regenix share price from 38p to 7p?
Available data shows the share price declined from approximately 38.00p in July 2025 to 7.25p by April 2026. Specific catalysts for this decline are not documented in current search results. Investors should consult RNS announcements for any disclosed company developments during this period.
Where can I buy Tissue Regenix shares?
Tissue Regenix shares trade on the London Stock Exchange and can be purchased through any UK-regulated brokerage offering LSE access. Investors should verify the broker’s suitability for trading AIM-listed stocks and understand the risks associated with micro-cap investments.
What is the analyst target for Tissue Regenix?
One analyst source has established a price target of 85.00p for Tissue Regenix, representing approximately 1,072% upside from the current 7.25p price. This target should be verified for currency and represents a single source rather than consolidated analyst consensus.
Does Tissue Regenix pay dividends?
Given the negative earnings per share forecast of -$0.01 and negative P/E ratio, Tissue Regenix does not appear positioned to pay dividends. Growth-stage medtech companies typically reinvest operating losses into research and development rather than distributing cash to shareholders.
Amelia Grant is Local Government Editor at RegionalReport.co.uk, covering council decisions, regional public policy, combined authorities, planning, housing and transport.